{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"62"}]}],"title":"Patients with event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"214"}]}],"title":"Patients without events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"276"}],"units":"Participants"}],"description":"Overall survival was determined from the date of randomization to the date of death (OS event) irrespective of cause. Patients who had not died at the time of the final analysis (clinical data cut-off) were censored at the date of the last contact.","groups":[{"description":"Fludarabine+cyclophosphamide (FC) intravenously for a total of 6 treatment cycles at intervals of 28 days. Fludarabine: 25 mg/m² IV on Days 1, 2, 3 for 6 cycles. Cyclophosphamide: 250 mg/m² IV on Days 1, 2, 3 for 6 cycles.","id":"OG000","title":"Fludarabine+Cyclophosphamide (FC)"},{"description":"Rituximab and FC intravenously for a total of 6 treatment cycles at intervals of 28 days. Cycle 1: rituximab 375 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 2, 3, 4; cyclophosphamide 250 mg/m² IV on Days 2, 3, 4. Cycles 2-6: rituximab 500 mg/m² IV on Day 1; fludarabine 25 mg/m² IV on Days 1, 2, 3; cyclophosphamide 250 mg/m² IV on Days 1, 2, 3.","id":"OG001","title":"Fludarabine+Cyclophosphamide+Rituximab (FCR)"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population was comprised of all patients randomized in the study, irrespective of whether they received treatment or not.","reportingStatus":"POSTED","timeFrame":"Mean observation time at time of analysis was approximately 26 months","title":"Number of Participants With Overall Survival (OS) Events","type":"SECONDARY","unitOfMeasure":"participants"}